Genmab A/S (NASDAQ:GMAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Genmab A/S (NASDAQ:GMAB - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the thirteen analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $39.17.

Several equities research analysts have recently weighed in on the company. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Truist Financial reduced their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Wall Street Zen lowered Genmab A/S from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Sanford C. Bernstein lowered Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st.

Institutional Investors Weigh In On Genmab A/S

A number of large investors have recently bought and sold shares of GMAB. EverSource Wealth Advisors LLC grew its position in Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after acquiring an additional 939 shares during the last quarter. Headlands Technologies LLC lifted its holdings in Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after buying an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after buying an additional 1,070 shares in the last quarter. Lindbrook Capital LLC lifted its holdings in Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after buying an additional 950 shares in the last quarter. Finally, Barclays PLC lifted its holdings in Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after buying an additional 2,285 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Trading Up 0.2%

GMAB traded up $0.04 during trading hours on Friday, hitting $22.86. The company's stock had a trading volume of 1,621,739 shares, compared to its average volume of 1,173,065. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $28.56. The firm has a market capitalization of $14.66 billion, a PE ratio of 13.14, a PEG ratio of 2.65 and a beta of 0.96. The company has a 50-day simple moving average of $20.65 and a 200 day simple moving average of $20.74.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. The firm had revenue of $715.00 million for the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Research analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.